昭衍新药的前世今生:冯宇霞掌舵二十余年,药物非临床研究服务营收占比超95%,深耕CRO领域持续扩张

新浪财经
Oct 30, 2025

登录新浪财经APP 搜索【信披】查看更多考评等级昭衍新药成立于1998年2月25日,于2017年8月25日在上海证券交易所上市,注册地址和办公地址均涉及北京市,办公地址还包括香港。公司是国内非临床安评行业的领先龙头,以药物非临床安全性评价服务为主,具备稀缺的技术壁垒和全产业链优势。公司主营业务为以药物非临床安全性评价服务为主的药物临床前研究服务和实验动物及附属产品的销售业务,所属申万行业为医药生物...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10